Bupropion

• 

  Subject Areas on Research

  • A 102-center prospective study of seizure in association with bupropion. 
  • A Pilot Trial Examining African American and White Responses to Algorithm-Guided Smoking Cessation Medication Selection in Persons Living with HIV. 
  • A double-blind comparison of bupropion and amitriptyline in depressed inpatients. 
  • A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. 
  • A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. 
  • Adapting smoking cessation treatment according to initial response to precessation nicotine patch. 
  • Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. 
  • Bupropion SR in the naturalistic treatment of elderly patients with major depression. 
  • Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. 
  • Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. 
  • Bupropion for weight reduction. 
  • Bupropion in chronic low back pain. 
  • Bupropion sustained release: a therapeutic overview. 
  • Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial. 
  • Bupropion-varenicline interactions and nicotine self-administration behavior in rats. 
  • Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. 
  • Combination Varenicline/Bupropion Treatment Benefits Highly Dependent Smokers in an Adaptive Smoking Cessation Paradigm. 
  • Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. 
  • Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. 
  • Cost-effectiveness analysis of the first-line therapies for nicotine dependence. 
  • Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. 
  • D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell. 
  • Design considerations for a study to evaluate the impact of smoking cessation treatment on stimulant use outcomes in stimulant-dependent individuals. 
  • Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. 
  • Does Extended Pre Quit Bupropion Aid in Extinguishing Smoking Behavior? 
  • Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs. 
  • Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. 
  • Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. 
  • Forms of atypical depression and their response to antidepressant drugs. 
  • Functional status in depressed patients: the relationship to disease severity and disease resolution. 
  • Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. 
  • Mobile contingency management as an adjunctive smoking cessation treatment for smokers with posttraumatic stress disorder. 
  • Molecular genetics of successful smoking cessation: convergent genome-wide association study results. 
  • Multicomponent smoking cessation treatment including mobile contingency management in homeless veterans. 
  • New findings on nicotine addiction and treatment. 
  • Omission of bupropion as a recommended treatment for PTSD. 
  • Outcomes from an outpatient smoking-cessation clinic. 
  • Patient-Informed Treatment Development of Behavioral Smoking Cessation for People With Schizophrenia. 
  • Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. 
  • Public health clinical demonstration project for smoking cessation in american veterans who served since september 11, 2001. 
  • Public health clinical demonstration project for smoking cessation in veterans with posttraumatic stress disorder. 
  • Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. 
  • Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program. 
  • Rational design of a combination medication for the treatment of obesity. 
  • Recommendations for high-priority research on cancer-related fatigue in children and adults. 
  • Response to Gorelick. 
  • Review of the cardiovascular effects of heterocyclic antidepressants. 
  • Second-generation antidepressants for preventing seasonal affective disorder in adults. 
  • Seizures and bupropion: a review. 
  • Serum bupropion levels in 2 breastfeeding mother-infant pairs. 
  • Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances. 
  • Suicide in pregnancy. 
  • The use of pharmacotherapies for smoking cessation during pregnancy. 
  • Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density. 
  • Twenty-first century tobacco use: it is not just a risk factor anymore. 
  • Use of Prescription Smoking Cessation Medications After Myocardial Infarction Among Older Patients in Community Practice. 
  • Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation program. 
  • Zyban: two products, two uses--too confusing?